LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
PRPO
Precipio, Inc.
There isn't enough reported data to score PRPO yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
PRPO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Healthy | |
| Strong |
PRPO's revenue, cash flow and balance sheet are currently healthy, but its profitability is under pressure.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
PRPO PE Valuation
PRPO has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
PRPO Forward outlook
There aren't enough analyst estimates for PRPO to show an outlook.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over PRPO on earnings quality, reporting a profit while its opponent remains loss making.
PRPO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.57 | +$0.24 |
| Q2 2026 | -$0.62 | +$0.56 |
| Q1 2026 | -$0.45 | +$1.61 |
| Q4 2025 | -$0.23 | +$2.70 |
| Q3 2025 | -$0.81 | +$1.24 |
| Q2 2025 | -$1.18 | +$1.49 |
| Q1 2025 | -$2.06 | +$1.58 |
| Q4 2024 | -$2.93 | +$1.85 |
PRPO is still losing money, but far less than before: $0.57 per share over the past year, against $52.60 at its worst in early 2020.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over PRPO on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over PRPO on profitability, with a higher operating margin.
PRPO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $7.3M | +8.3% |
| Q2 2026 | $7M | +24% |
| Q1 2026 | $6.7M | +36% |
| Q4 2025 | $6.7M | +23% |
| Q3 2025 | $6.8M | +30% |
| Q2 2025 | $5.7M | +27% |
| Q1 2025 | $4.9M | +44% |
| Q4 2024 | $5.5M | +26% |
PRPO's revenue has grown year over year for 15 quarters in a row: $7M last quarter, up 8.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 0% | +0.9 points |
| Q2 2026 | -8.5% | +6 points |
| Q1 2026 | -21% | -3.9 points |
| Q4 2025 | 8.1% | +14 points |
| Q3 2025 | -0.9% | +11 points |
| Q2 2025 | -15% | +13 points |
| Q1 2025 | -17% | +43 points |
| Q4 2024 | -6.2% | +14 points |
PRPO's operating margin was 0% last quarter, up 0.9 points from the same quarter a year ago, near the top of its range since 2019.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
PRPO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $554K | +$598K |
| Q2 2026 | $528K | +80% |
| Q1 2026 | $14K | +$196K |
| Q4 2025 | $291K | -44% |
| Q3 2025 | -$44K | +$24K |
| Q4 2024 | $521K | +702% |
| Q3 2024 | -$68K | +$851K |
| Q4 2023 | $65K | +$1.6M |
PRPO has the edge over LLY on cash flow, with more consistent year-over-year improvement.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over PRPO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
PRPO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +3.5K shares |
| 1 year | +9.4% | +153K shares |
| 3 years | +28% | +396K shares |
| 5 years | +58% | +655K shares |
| Available history | +529% | +1.5M shares |
PRPO has 2M diluted shares, up 9.4% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
PRPO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2025 | -59.9x | Net Cash |
PRPO has more cash than debt.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
PRPO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 49.6 | Neutral |
| Stochastic | 14.4 | Oversold |
PRPO's weekly RSI is 50 (neutral) and its Stochastic is 14 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
PRPO PE vs Healthcare Sector
PRPO has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over PRPO on trend strength, trading above more of its moving averages.
PRPO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $21.4 | 8.6% above |
| 20 week MA | $23.9 | 2.8% below |
| 50 week MA | $24.6 | 5.3% below |
| 100 week MA | $18.2 | 27% above |
| 200 week MA | $13.1 | 78% above |
PRPO's trend is mixed: it's above three of its five weekly moving averages, and 78% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over PRPO on returns for 2026, with the stronger performance.
PRPO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $40.8 | $41.8 | +2.5% |
| 2021 | $41.8 | $35.6 | -15% |
| 2022 | $35.6 | $11.0 | -69% |
| 2023 | $11.0 | $6.50 | -41% |
| 2024 | $6.50 | $5.51 | -15% |
| 2025 | $5.51 | $23.8 | +331% |
| 2026 YTD | $23.8 | $23.3 | -2.1% |
PRPO's yearly returns have swung widely, from +331% in 2025 to −69% in 2022. It's down 2.1% so far in 2026.